Hepatitis delta virus (HDV) is a satellite RNA virus that requires the presence of hepatitis B virus (HBV) for its replication. HDV/HBV co-infection is often associated with a faster disease progression of chronic hepatitis in comparison to HBV mono-infection. Therefore, the development of novel antiviral therapies targeting HDV represents a high priority and an urgent medical need. In this review, we summarize the ongoing efforts to evaluate promising HDV-specific drugs, such as lonafarnib (LNF), pegylated interferon lambda (PEG-IFN-λ) and their use as a combination therapy. Furthermore, we review the most recent developments in the area of anti-HBV drugs with potential effects against HDV, including therapeutic agents targeting hepatitis B surface antigen (HBsAg) expression, secretion and function. Finally, we consider the important insights that have emerged from the development of these potential antiviral strategies, as well as the intriguing questions that remain to be elucidated in this rapidly changing field.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/liv.15417 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An hepatitis B and D virus infection model using human pluripotent stem cell-derived hepatocytes.
EMBO Rep
October 2024
Schaller Research Group, Department of Infectious Diseases, Virology, Heidelberg University, Medical Faculty Heidelberg, Heidelberg, Germany.
Current culture systems available for studying hepatitis D virus (HDV) are suboptimal. In this study, we demonstrate that hepatocyte-like cells (HLCs) derived from human pluripotent stem cells (hPSCs) are fully permissive to HDV infection across various tested genotypes. When co-infected with the helper hepatitis B virus (HBV) or transduced to express the HBV envelope protein HBsAg, HLCs effectively release infectious progeny virions.
View Article and Find Full Text PDFPrevalence of Hepatitis D in People Living with HIV: A National Cross-Sectional Pilot Study.
Viruses
June 2024
School of Medicine, University of Patras, 26504 Patras, Greece.
Article Synopsis
- - This study investigates the prevalence of hepatitis D virus (HDV) among people living with HIV (PLWHIV) in Greece, highlighting the importance of understanding the impact of co-infections on liver disease as new treatments emerge.
- - A total of 696 serum samples from PLWHIV were analyzed, revealing that the majority of participants were male (93%) with a median age of 54 and a long history on antiretroviral therapy, while additional findings showed seroprevalence for other viruses like HCV and HAV.
- - Results showed a low HDV prevalence in the study group, with only 3% testing positive for anti-HDV IgG antibodies and none for HDV RNA, indicating fewer
Prospective study of hepatitis B and D epidemiology and risk factors in Romania: A 10-year update.
World J Hepatol
April 2024
Institute of Gastroenterology and Hepatology, Saint Spiridon County Hospital, Iasi 700111, Romania.
Article Synopsis
- Hepatitis D virus (HDV) infection poses a significant public health problem globally, particularly in those also infected with hepatitis B virus (HBV), leading to more severe liver complications and higher mortality rates compared to HBV alone.
- A study conducted in Romania from January to July 2022 enrolled adults with HBV to explore the epidemiology and risk factors associated with HBV/HDV coinfection, revealing a prevalence rate of 3.8% for HBV and 33.1% for coinfection among those tested.
- Key risk factors for HBV/HDV coinfection included being female, having a history of imprisonment, being older at diagnosis, and having sexual contact with individuals known to have viral hepatitis
Emerging anti-HDV drugs and HBV cure strategies with anti-HDV activity.
Liver Int
August 2023
INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon (CRCL), Lyon, France.
Hepatitis delta virus (HDV) is a satellite RNA virus that requires the presence of hepatitis B virus (HBV) for its replication. HDV/HBV co-infection is often associated with a faster disease progression of chronic hepatitis in comparison to HBV mono-infection. Therefore, the development of novel antiviral therapies targeting HDV represents a high priority and an urgent medical need.
View Article and Find Full Text PDFChanging epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan.
Sci Rep
April 2021
Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC.
The spreading of viral hepatitis among injecting drug users (IDU) is an emerging public health concern. This study explored the prevalence and the risks of hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus (HDV) among IDU-dominant prisoners in Taiwan. HBV surface antigen (HBsAg), antibodies to HCV (anti-HCV) and HDV (anti-HDV), viral load and HCV genotypes were measured in 1137(67.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!